Naximin spray 0.05mg + 5mg / dose, 15ml

As part of a combination therapy to reduce swelling of the nasopharyngeal mucosa:

• acute respiratory diseases with symptoms of rhinitis; acute allergic rhinitis;

• vasomotor rhinitis;

• sinusitis;

• otitis media.

  To facilitate rhinoscopy, restore disturbed nasal breathing after surgical interventions in the nasal cavity.

Intranasally.

Concentration 0.05 mg + 5 mg / dose - for children from 2 to 6 years old.

Concentration 0.1 mg + 5 mg / dose - for adults and children over 6 years old.

Remove the protective cap. The bottle is ready to use.

Before the first use or after a long break from using the spray, press the dispensing nozzle several times until a uniform spray appears.

When using the spray, the bottle must be kept in an upright position. To ensure accurate dosing of the drug, when pressing the dispensing nozzle, it is necessary to lower it down until it stops.

During injection, you need to inhale easily through your nose. One injection into each nasal passage 3-4 times / day. The duration of therapy is 5-7 days. Should not be used for more than 7 days. The duration of the use of the drug in children is established after consultation with a doctor.

Reapplication is possible only after a break of several days.

If after 5 days of treatment there is no improvement or symptoms worsen, or new symptoms appear, you should consult your doctor.

The drug should be used only according to the indications, the route of administration and the doses indicated in the instructions.

Dosed nasal spray in the form of a clear, colorless or slightly yellowish solution.

1 dose

xylometazoline hydrochloride 0.05 mg

dexpanthenol 5 mg

Excipients: potassium dihydrogen phosphate - 0.9 mg, sodium hydrogen phosphate dihydrate - 0.015 mg, water d / i - up to 100 ?l.

• Hypersensitivity to the components of the drug;

• arterial hypertension;

• tachycardia;

• severe atherosclerosis;

• hyperthyroidism;

• glaucoma;

• atrophic rhinitis;

• dry rhinitis;

• porphyria;

• hyperplasia of the prostate;

• surgical interventions on the meninges (in history);

• simultaneous use with MAO inhibitors and tricyclic antidepressants;

• pregnancy;

• breastfeeding period;

• for a concentration of 0.05 mg + 5 mg / dose - children under 2 years of age;

• for a concentration of 0.1 mg + 5 mg / dose - children under 6 years of age.

  Carefully

• Diabetes mellitus, pheochromocytoma, diseases of the cardiovascular system (including ischemic heart disease), hypersensitivity to the action of adrenergic drugs, accompanied by insomnia, dizziness, arrhythmia, tremor, increased blood pressure.

pharmachologic effect

Xylometazoline belongs to the group of local vasoconstrictor agents (decongestants) with alpha-adrenomimetic activity, causes narrowing of the blood vessels of the nasal mucosa, restores the patency of the nasal passages, and facilitates nasal breathing. The effect of the drug usually occurs within a few minutes after its use and lasts up to 10 hours.

Dexpanthenol - a B vitamin - a derivative of pantothenic acid. Dexpanthenol is converted in the body into pantothenic acid, which is an integral part of coenzyme A (Co A) and is involved in acetylation processes, carbohydrate and fat metabolism, in the synthesis of acetylcholine, corticosteroids, porphyrins; stimulates the regeneration of the skin, mucous membranes, normalizes cell metabolism, accelerates mitosis and increases the strength of collagen fibers. It has a regenerating, metabolic and mild anti-inflammatory effect.

Pharmacokinetics

Xylometazoline, when applied topically, is practically not absorbed, plasma concentrations are so small that they cannot be determined by modern analytical methods.

Dexpanthenol, when applied topically, is rapidly absorbed by the skin and turns into pantothenic acid, binds to plasma proteins (mainly beta-globulin and albumin). Its concentration in blood is 0.5-1 mg / l, in blood serum - 100 ?g / l. Pantothenic acid is not metabolized in the body (except for inclusion in Co-A), it is excreted unchanged.

Side effect

From the nervous system: very rarely - anxiety, insomnia, headache, fatigue (drowsiness), hallucinations (mainly in children).

From the side of the cardiovascular system: rarely - palpitations, tachycardia, increased blood pressure; very rarely - arrhythmia.

From the respiratory system: very rarely - swelling of the nasal mucosa, hypersecretion, nosebleeds; the frequency is not known - burning and dryness of the nasal mucosa, sneezing.

From the musculoskeletal system: very rarely - convulsions (especially in children).

From the immune system: very rarely - allergic reactions (angioedema, skin rash, itching).

If any of these side effects are aggravated, or any other side effects are noted, you should inform your doctor.

Application during pregnancy and lactation

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Application in children

Contraindications:

? for a concentration of 0.05 mg + 5 mg / dose - children under 2 years of age;

? for a concentration of 0.1 mg + 5 mg / dose - children under 6 years of age.

Use in elderly patients

Use with caution to avoid the risk of exacerbation of chronic diseases.

special instructions

Before use, you must clean the nasal passages.

The duration of the use of the drug in children is established after consultation with a doctor.

Influence on the ability to drive vehicles and mechanisms

When using the drug in accordance with these instructions for use, the drug does not affect the ability to drive vehicles, mechanisms, however, when undesirable phenomena appear, you should refrain from performing these activities.

Overdose

Symptoms: in cases of overdose or accidental oral administration, mydriasis, nausea, vomiting, cyanosis, fever, convulsions, tachycardia, cardiac arrhythmias, vascular insufficiency, cardiac arrest, arterial hypertension, pulmonary edema, respiratory dysfunction, hallucinations may occur. Patients may also develop symptoms of CNS depression, accompanied by drowsiness, a decrease in body temperature, bradycardia, shock, respiratory arrest, and coma.

Treatment: the use of activated carbon, gastric lavage, oxygen ventilation of the lungs. To lower blood pressure, 5 mg of phentolamine in 0.9% sodium chloride solution is prescribed by slow intravenous administration or 100 mg of phentolamine orally. Vasoconstrictor drugs are contraindicated. If necessary, use antipyretic and anticonvulsants.

Drug interactions

The concomitant use of MAO inhibitors and tricyclic antidepressants can lead to an increase in blood pressure due to the effect of these drugs on the cardiovascular system.